Isobutylbenzene

Isobutylbenzene

SCHEMBL6544201

CC(C)(C)N.CC(C)Cc1ccccc1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEIDH1

The experimentally established mechanism targets of Isobutylbenzene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.58
SIGMAR1 Q99720 4/20 0.58
SLC6A2 P23975 3/20 0.58
MAOA P21397 1/20 0.58
SLC6A4 P31645 1/20 0.58
SLC6A3 Q01959 1/20 0.58
CYP2A6 P11509 1/20 0.58
ADORA2A P29274 1/20 0.58
ADORA1 P30542 1/20 0.58
CYP2D6 P10635 1/20 0.54
EPHX1 P07099 1/20 0.50
SLC18A2 Q05940 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TRPA1 O75762 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isobutylbenzene SCHEMBL57393 0.88 SIGMAR1 (0.64) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL7493657 0.88 SIGMAR1 (0.64) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL2571645 0.88 SIGMAR1 (0.64) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL6891614 0.85 SIGMAR1 (0.61) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL1894392 0.85 SIGMAR1 (0.61) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL11468970 0.85 TAAR1 (0.61) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL363626 0.85 TAAR1 (0.61) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL31498540 0.85 SIGMAR1 (0.61) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL31284788 0.85 SIGMAR1 (0.61) TAAR1SIGMAR1SLC6A2MAOASLC6A4
Isobutylbenzene SCHEMBL11839466 0.83 TAAR1 (0.58) TAAR1SIGMAR1SLC6A2MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040122270-A1 In-situ polymerization of monoethylenically unsaturated monomers with secondary amines BAYER AKTIENGESELLSCHAFT (DE) 2004-06-24 US disclosed
EP-1428838-A1 In situ-polymerization of monoethylenically unsaturated monomers with secondary amines Bayer MaterialScience AG (DE) 2004-06-16 EP disclosed
EP-1428839-A1 In-situ polymerization of monoethylenically unsaturated monomers with secondary amines Bayer MaterialScience AG (DE) 2004-06-16 EP disclosed
US-6686424-B2 USE IN RADICAL POLYMERIZATION; REACTING AN OXIDIZING AGENT WITH A STERICALLY HINDERED SECONDARY AMINE TO PRODUCE A NITROXY RADICAL; ADDING TO THE NITROXY RADICAL ONE OR MORE VINYL MONOMER BAYER AKTIENGESELLSCHAFT (DE) 2004-02-03 US disclosed
EP-1375476-A1 A new process for the synthesis of alkoxyamines active in controlled radical polymerization Bayer Aktiengesellschaft (DE) 2004-01-02 EP disclosed
EP-1375457-A1 One-pot process for the preparation of functionalized alkoxyamines Bayer Aktiengesellschaft (DE) 2004-01-02 EP disclosed
US-20040002606-A1 Process for the synthesis for alkoxy amines and their use in controlled radical polymerization BAYER AKTIENGESELLSCHAFT (DE) 2004-01-01 US disclosed
US-20030236368-A1 PREPARATION OF FUNCTIONALIZED ALKOXYAMINE INITIATOR AND ITS USE BAYER AKTIENGESELLSCHAFT (DE) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236368-A1 PREPARATION OF FUNCTIONALIZED ALKOXYAMINE INITIATOR AND ITS USE NOS1, NOS2, CBR1 TAAR1 205/4885SIGMAR1 333/4885SLC6A2 2402/4885
US-20040002606-A1 Process for the synthesis for alkoxy amines and their use in controlled radical polymerization ALKBH3, MAOB, ALKBH1 TAAR1 75/4885SIGMAR1 223/4885SLC6A2 1928/4885
US-20040122270-A1 In-situ polymerization of monoethylenically unsaturated monomers with secondary amines ALOX5, PARG, FASN TAAR1 587/4885SIGMAR1 514/4885SLC6A2 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.